Monocyte‐Mimetic Contrast Agent Enables Targeted and Sensitive Magnetic Resonance Imaging of Atherosclerotic Lesions
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202502001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Joshua Rousseau und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological and Health Systems Engineering (SBHSE), Arizona State University, Tempe, AZ, 85287, USA. Hauptthemen laut MEDLINE: Contrast Media, Magnetic Resonance Imaging, Monocytes, Atherosclerosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: NHLBI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Superparamagnetic iron oxide nanoparticles (SPION) are investigated as T2 contrast agents for magnetic resonance imaging (MRI) of atherosclerosis. However, their nonspecific biodistribution and low plaque‐site bioavailability limit their translational potential. To address these challenges, monocyte membrane‐cloaked polymeric nanoparticles encapsulating SPION (MoNP‐SPION) to enhance plaque‐specific accumulation is developed. Physicochemical characterization confirmed successful MoNP‐SPION formulation, with a hydrodynamic size of ≈271 nm, SPION loading efficiency of 8.5%, and r2 relaxivity of 397.7 mM −1 s −1 . In vitro assays and phantom imaging demonstrated that MoNP‐SPION exhibited significantly enhanced targeting efficiency toward TNFα‐activated endothelial cells while minimizing uptake by monocytes and macrophages compared to its constituents. T2*‐weighted ex vivo MRI confirmed the preferential accumulation of MoNP‐SPION in atheroprone regions while sparing lesion‐free areas of the vasculature. In vivo MRI of atherosclerotic mice revealed that MoNP‐SPION, but not the uncoated counterpart or free SPION, induced strong T2*‐weighted signal reductions at the carotid bifurcations and aortic root, areas with significant plaque development, confirming its ability to enhance atherosclerosis imaging. Furthermore, toxicity assessments demonstrated the biocompatibility of MoNP‐SPION. Together, the findings highlight MoNP‐SPION as a promising biomimetic contrast agent for improving MRI‐based diagnosis of atherosclerosis, with potential applications in monitoring plaque progression and treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological and Health Systems Engineering (SBHSE), Arizona State University, Tempe, AZ, 85287, USA.
- School for Engineering of Matter, Transport and Energy (SEMTE), Arizona State University, Tempe, AZ, 85287, USA.
- Knowledge Enterprise Biosciences Research Preclinical Imaging Center, Arizona State University, Tempe, AZ, 85287, USA.
ORCID-Profile: Kuei-Chun Wang
Förderung
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Rousseau, J., Wang, T. Y., McClendon, S., Ortega, D., Orlando, M., Beeman, S. C., Bartelle, B. B., & Wang, K. C. (2026). Monocyte‐Mimetic Contrast Agent Enables Targeted and Sensitive Magnetic Resonance Imaging of Atherosclerotic Lesions. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202502001
Vancouver
Rousseau J, Wang TY, McClendon S, Ortega D, Orlando M, Beeman SC, et al. Monocyte‐Mimetic Contrast Agent Enables Targeted and Sensitive Magnetic Resonance Imaging of Atherosclerotic Lesions. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202502001
BibTeX
@article{Rousseau2026,
author = {Rousseau, Joshua and Wang, Ting-Yun and McClendon, Samantha and Ortega, Dakota and Orlando, Mark and Beeman, Scott C and Bartelle, Benjamin B and Wang, Kuei-Chun},
title = {Monocyte‐Mimetic Contrast Agent Enables Targeted and Sensitive Magnetic Resonance Imaging of Atherosclerotic Lesions},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202502001}
}
EUVIMED